Lundbeck Inc. Embarks on Research Initiative to Identify and Develop Therapies that May Slow or Halt the Progression of Huntington's Disease
DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck Inc. today launched a Huntington’s disease (HD) research initiative to identify and ultimately commercialize therapies that may slow or halt the progression of the disease. The research will be driven by collaborations with academic institutions and companies with promising compounds in development.